NCT02871570View on ClinicalTrials.gov

A Study to Evaluate the Effect of IV Doses of Rivipansel in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

February 28, 2017

Study Completion Date

March 31, 2017

Conditions
Moderate Hepatic ImpairmentNormal Hepatic Function
Interventions
DRUG

Rivipansel

A single dose of IV Rivipansel over 20 minutes

Trial Locations (1)

32809

Orlando Clincial Research Center, Orlando

All Listed Sponsors
lead

GlycoMimetics Incorporated

INDUSTRY

NCT02871570 - A Study to Evaluate the Effect of IV Doses of Rivipansel in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function | Biotech Hunter | Biotech Hunter